** Shares of biotech firm Terns Pharma TERN.O up 12.5% at $56.2 premarket
** Financial Times reports, citing people familiar with the matter, that drugmaker Merck MRK.N is nearing a roughly $6 bln all-cash deal to acquire TERN
** Negotiations between the companies are said to be in advanced stages, with an agreement potentially expected within the next few days - report says
** Merck and Terns Pharma did not immediately respond to Reuters requests for comment
** MRK shares edge 0.3% higher in light volumes
** Potential acquisition comes as MRK continues to reshape its oncology strategy
** As of last close, TERN stock up 23.7% YTD, following a more than sevenfold rise in 2025
(Reporting by Tharuniyaa Lakshmi in Bengaluru)
((tharuniyaa@thomsonreuters.com))